Vertex Pharmaceuticals recently reported clinical data showing that CASGEVY helped all evaluable children aged 5–11 with ...
Wondering whether Vertex Pharmaceuticals is still worth buying at around $452 a share, or if the big gains are already behind ...
So far, the company's commercialized drugs have delivered billions of dollars in revenue. For example, in the latest quarter, ...
These companies could innovate their way to success.
Zacks Investment Research on MSN
Investors heavily search Vertex Pharmaceuticals Incorporated (VRTX): Here is what you need to know
Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...
Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...
With a volume of 1,752,912, the price of VRTX is up 1.48% at $439.58. RSI indicators hint that the underlying stock may be ...
Vertex has achieved significant growth in recent years, but things have slowed lately. The company has many potential catalysts that could accelerate its growth rate. Vertex's pipeline highlights many ...
Vertex Pharmaceuticals presents clinical data demonstrating benefits of Casgevy in SCD and TDT patients aged 5+ at ASH ...
Vertex Pharmaceuticals said on Saturday its gene therapy helped children aged between 5 and 11 years with sickle cell disease ...
US biopharma Vertex Pharmaceuticals today announced data from multiple studies demonstrating the clinical benefits of Casgevy ...
Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about 16% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback